Sangamo BioSciences (SGMO) : 4 investment research analysts covering Sangamo BioSciences (SGMO) have an average price target of $15.25 for the near short term. The highest target price given by the Brokerage Firm to the stock is $30 and the lowest target is $8 for the short term. Analysts expect the variance to be within $10.18 of the average price.
Sangamo BioSciences (SGMO) : 6 analysts are covering Sangamo BioSciences (SGMO) and their average rating on the stock is 1.33, which is read as a Strong Buy. 5 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Also, Janney Capital downgrades its view on Sangamo BioSciences (NASDAQ:SGMO) according to the research report released by the firm to its investors. The shares have now been rated Neutral by the stock experts at the ratings house. Earlier, the shares had a rating of Buy. The rating by the firm was issued on August 4, 2016.
Sangamo BioSciences (NASDAQ:SGMO): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $4.27 and $4.18 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $4.34. The buying momentum continued till the end and the stock did not give up its gains. It closed at $4.33, notching a gain of 0.93% for the day. The total traded volume was 787,559 . The stock had closed at $4.29 on the previous day.
Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research development and commercialization of engineered DNA-binding proteins as therapeutic products. The main focus for the Company is the development of novel human therapeutics and it is building a pipeline of ZFP Therapeutics. The Companys lead ZFP Therapeutic SB-728-T, a ZFN-modified autologous T-cell product is under development for the treatment of HIV/AIDS. The Companys clinical stage programs also include SB-728-HSPC for the treatment of HIV/AIDS, SB-BCLmR-HSPC to treat Beta-thalassemia major and CERE-110 for the treatment of Alzheimers disease. Its pre-clinical products include SB-913 for the treatment of Hunter Syndrome and SB-318 for the treatment of Hurler Syndrome.